ascopubs.org

Concordance of PD-L1 combined positive score (CPS) analysis between primary gastric cancer and matched peritoneal metastasis.

The role of determining HER2neu status in patients with gastric cancer. Advanced signet ring cell type gastroesophageal cancers in Latin American patients age 40 and below: A summary of one tertiary ...
ascopubs.org

Performance validation of an artificial intelligence-powered PD-L1 combined positive score analyzer in six cancer types.

Using EHR data and machine learning approach to facilitate the identification of patients with lung cancer from a pan-cancer cohort. Novel machine learning algorithm to predict response to ...
Medscape

PD-L1 Did Not Predict Immunotherapy Benefit in Cervical Cancer

Findings of the BEATcc trial suggest PD-L1 status is not a reliable biomarker for guiding immunotherapy selection in patients with recurrent or metastatic cervical cancer, potentially simplifying ...
Seeking Alpha

Immutep’s Efti in Combination with KEYTRUDA® (pembrolizumab) Drives Strong Overall Survival in Head and Neck Cancer with CPS <1

Complementary nature of these two immunotherapies leads to excellent 17.6-month median Overall Survival in head and neck cancer patients with PD-L1 CPS <1 Mature overall survival data builds on ...
Nasdaq

Merck Receives Positive EU CHMP Opinion for KEYTRUDA® (pembrolizumab) Plus Chemotherapy as First-Line Treatment for HER2-Negative Advanced Gastric or Gastroesophageal Junction ...

If approved, a KEYTRUDA combination would become an option in the EU for the treatment of both HER2-negative and HER2-positive advanced gastric or GEJ adenocarcinoma in tumors expressing PD-L1 (CPS ≥1 ...
Cure Today

First-Line Keytruda Combo Elicits OS Results in Head and Neck Cancers

Keytruda and Efti combination therapy achieved a median overall survival of 17.6 months in head and neck squamous cell carcinoma with PD-L1 CPS less than one. The combination therapy demonstrated a ...
MedPage Today

Immunotherapy Combo Active in Advanced PD-L1-Negative HNSCC

A chemotherapy-free regimen combining the investigational therapy eftilagimod alpha with pembrolizumab (Keytruda) showed promising efficacy in a small cohort of patients with recurrent or metastatic ...
MedPage Today

Pembrolizumab in First-Line Boosts PFS in HER2-Positive Stomach Cancer

MADRID -- Including pembrolizumab (Keytruda) in the first-line treatment of metastatic HER2-positive gastric or gastroesophageal cancer improved progression-free survival (PFS), but potential harm was ...
CURE

Keytruda Combo Extends Survival in Ovarian Cancer Trial: Expert Insights

Pembrolizumab plus weekly paclitaxel, with investigator-choice bevacizumab, achieved statistically significant PFS and OS ...
Seeking Alpha

KEYTRUDA® (pembrolizumab) and KEYTRUDA QLEX™ (pembrolizumab and berahyaluronidase alfa-pmph), Plus Paclitaxel ± Bevacizumab, Approved for Certain Adults with PD-L1+ (CPS ...

KEYTRUDA and KEYTRUDA QLEX are the first and only PD-1 inhibitors approved for adults with platinum-resistant epithelial ovarian, fallopian tube or primary peritoneal carcinoma with PD-L1+ tumors ...
Medscape

New First-Line Option in Head and Neck Cancer: 'Practice Changing'

CHICAGO — First-line therapy options for head and neck cancer should now include immunotherapy with pembrolizumab (Keytruda, Merck) given alone or in combination with chemotherapy (CT), says experts ...